Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry

被引:128
作者
Kadian, Naveen [1 ]
Raju, Kanumuri Siva Rama [1 ,2 ]
Rashid, Mamunur [1 ]
Malik, Mohd Yaseen [1 ]
Taneja, Isha [1 ,2 ]
Wahajuddin, Muhammad [1 ,2 ]
机构
[1] CSIR Cent Drug Res Inst, Dept Metab & Pharmacokinet, Lucknow 226031, Uttar Pradesh, India
[2] Acad Sci & Ind Res, New Delhi, India
关键词
Bioanalysis; Validation; Regulatory guidance; USFDA; ANVISA; MHLW; EMA; ANALYTE STABILITY; ASSAYS; SELECTIVITY; ISSUES; PLASMA; IMPACT; MS/MS;
D O I
10.1016/j.jpba.2016.03.052
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The concepts, importance, and application of bioanalytical method validation have been discussed for a long time and validation of bioanalytical methods is widely accepted as pivotal before they are taken into routine use. United States Food and Drug Administration (USFDA) guidelines issued in 2001 have been referred for every guideline released ever since; may it be European Medical Agency (EMA) Europe, National Health Surveillance Agency (ANVISA) Brazil, Ministry of Health and Labour Welfare (MHLW) Japan or any other guideline in reference to bioanalytical method validation. After 12 years, USFDA released its new draft guideline for comments in 2013, which covers the latest parameters or topics encountered in bioanalytical method validation and approached towards the harmonization of bioanalytical method validation across the globe. Even though the regulatory agencies have general agreement, significant variations exist in acceptance criteria and methodology. The present review highlights the variations, similarities and comparison between bioanalytical method validation guidelines issued by major regulatory authorities worldwide. Additionally, other evaluation parameters such as matrix effect, incurred sample reanalysis including other stability aspects have been discussed to provide an ease of access for designing a bioanalytical method and its validation complying with the majority of drug authority guidelines. (C) 2016 Published by Elsevier B.V.
引用
收藏
页码:83 / 97
页数:15
相关论文
共 25 条
  • [1] Selectivity versus specificity in chromatographic analytical methods
    Aboul-Enein, HY
    [J]. ACCREDITATION AND QUALITY ASSURANCE, 2000, 5 (05) : 180 - 181
  • [2] Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods
    Almeida, AM
    Castel-Branco, MM
    Falcao, AC
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 774 (02): : 215 - 222
  • [3] [Anonymous], 2001, GUID IND BIOAN METH
  • [4] [Anonymous], GUID BIOAN METH VAL
  • [5] [Anonymous], 2013, Guidance for industry # 213
  • [6] Bergeron A, 2012, BIOANALYSIS, V4, P897, DOI [10.4155/bio.12.54, 10.4155/BIO.12.54]
  • [7] Bolton S., 2009, Pharmaceutical Statistics: Practical and Clinical Applications
  • [8] Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses
    Chambers, Erin
    Wagrowski-Diehl, Diane M.
    Lu, Ziling
    Mazzeo, Jeffrey R.
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2): : 22 - 34
  • [9] APPLICATION ISSUES IN BIOANALYTICAL METHOD VALIDATION, SAMPLE ANALYSIS AND DATA REPORTING
    DADGAR, D
    BURNETT, PE
    CHOC, MG
    GALLICANO, K
    HOOPER, JW
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 13 (02) : 89 - 97
  • [10] Issues in evaluation of bioanalytical method selectivity and drug stability
    Dadgar, D
    Burnett, PE
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 14 (1-2) : 23 - 31